|Table of Contents|

Research advances of CAR-NK cell therapy in solid tumors

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 05
Page:
964-968
Research Field:
Publishing date:

Info

Title:
Research advances of CAR-NK cell therapy in solid tumors
Author(s):
YAN Ji1; 2; YIN Gang1; DENG Guoying1
1.Shanghai First People's Hospital,Shanghai 201620,China;2.Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China.
Keywords:
chimeric antigen receptor; natural killer cells; solid tumors; immunotherapy
PACS:
R730.5
DOI:
10.3969/j.issn.1672-4992.2023.05.035
Abstract:
Tumor immune cell therapy has attracted much attention in recent years.Chimeric antigen receptor engineered T-cell (CAR-T) cells have been used to treat hematological malignancies with great success,but there are shortcomings in the treatment of solid tumors.Due to their ability to kill tumor cells differently from T cells,CAR-modified nature killer (NK) cells have gradually become a research hotspot.At present,extensive preclinical studies have proved the safety and efficacy of CAR-NK cell therapy,especially in the treatment of solid tumors,showing better application prospects than CAR-T cells.However,CAR-NK cell therapy still has some limitations,and further research is needed to achieve its clinical translation.

References:

［1］AMINI L,SILBERT SK,MAUDE SL,et al.Preparing for CAR T cell therapy: Patient selection,bridging therapies and lymphodepletion［J］.Nat Rev Clin Oncol,2022,19(5):342-355.
［2］STERNER,RC,STERNER,RM.CAR-T cell therapy: Current limitations and potential strategies［J］.Blood Cancer Journal,2021,11(4):69.
［3］MYERS JA,MILLER JS.Exploring the NK cell platform for cancer immunotherapy［J］.Nature Reviews Clinical Oncology,2021,18(2):85-100.
［4］SHIN MH,KIM J,LIM SA,et al.NK Cell-based immunotherapies in cancer［J］.Immune Network,2020,20(2):e14.
［5］XIE G,DONG H,LIANG Y,et al.CAR-NK cells: Apromising cellular immunotherapy for cancer［J］.EBioMedicine,2020,59:102975.
［6］DAHER M,REZVANI K.Outlook for new CAR-based therapies with a focus on CAR NK cells: What lies beyond CAR-engineered T cells in the race against cancer［J］.Cancer Discovery,2021,11(1):45-58.
［7］WANG W,JIANG J,WU C.CAR-NK for tumor immunotherapy: Clinical transformation and future prospects［J］.Cancer Letters,2020,472:175-180.
［8］WANG L,DOU M,MA Q,et al.Chimeric antigen receptor (CAR)-modified NK cells against cancer: Opportunities and challenges［J］.International Immunopharmacology,2019,74:105695.
［9］YILMAZ A,CUI H,CALIGIURI MA,et al.Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy［J］.Journal of Hematology & Oncology,2020,13(1):168.
［10］ABATE-DAGA D,DAVILA ML.CAR models: Next-generation CAR modifications for enhanced T-cell function［J］.Molecular Therapy Oncolytics,2016,3:16014.
［11］XIAO L,CEN D,GAN H,et al.Adoptive transfer of NKG2D CAR mRNA-engineered natural killer cells in colorectal cancer patients［J］.Molecular Therapy,2019,27(6):1114-1125.
［12］VIDARD L,DUREUIL C,BAUDHUIN J,et al.CD137 (4-1BB) engagement fine-tunes synergistic IL-15-and IL-21-Driven NK cell proliferation［J］.Journal of Immunology,2019,203(3):676-685.
［13］HUANG Y,ZENG J,LIU T,et al.DNAM1 and 2B4 costimulatory domains enhance the cytotoxicity of anti-GPC3 chimeric antigen receptor-modified natural killer cells against hepatocellular cancer cells in vitro［J］.Cancer Management and Research,2020,12:3247-3255.
［14］SIEMASZKO J,MARZEC-PRZYSZLAK A,BOGUNIA-KUBIK K.NKG2D natural killer cell receptor-a short description and potential clinical applications［J］.Cells,2021,10(6):1420.
［15］MULLER S,BEXTE T,GEBEL V,et al.High cytotoxic efficiency of lentivirally and alpharetrovirally engineered CD19-specific chimeric antigen receptor natural killer cells against acute lymphoblastic leukemia［J］.Frontiers in Immunology,2020,10:3123.
［16］INGEGNERE T,MARIOTTI FR,PELOSI A,et al.Human CAR NK cells: A new non-viral method allowing high efficient transfection and strong tumor cell killing［J］.Frontiers in Immunology,2019,10:957.
［17］WANG J,LUPO KB,CHAMBERS AM,et al.Purinergic targeting enhances immunotherapy of CD73+ solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells［J］.Journal for Immunotherapy of Cancer,2018,6(1):136.
［18］SUCK G,ODENDAHL M,NOWAKOWSKA P,et al.NK-92: an' off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy［J］.Cancer Immunology,Immunotherapy,2016,65(4):485-492.
［19］SUCK G,BRANCH DR,SMYTH MJ,et al.KHYG-1,a model for the study of enhanced natural killer cell cytotoxicity［J］.Experimental Hematology,2005,33(10):1160-1171.
［20］MILLER JS,SOIGNIER Y,PANOSKALTSIS-MORTARI A,et al.Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer［J］.Blood,2005,105(8):3051-3057.
［21］TANAKA J.Recent advances in chimeric antigen receptor natural killer cell therapy for overcoming intractable hematological malignancies［J］.Hematological Oncology,2021,39(1):11-19.
［22］YANG Y,BADETI S,TSENG HC,et al.Superior expansion and cytotoxicity of human primary NK and CAR-NK cells from various sources via enriched metabolic pathways［J］.Molecular Therapy Methods & Clinical Development,2020,18:428-445.
［23］SAETERSMOEN ML,HAMMER Q,VALAMEHR B,et al.Off-the-shelf cell therapy with induced pluripotent sTME cell-derived natural killer cells［J］.Seminars in Immunopathology,2019,41(1):59-68.
［24］UEDA T,KANEKO S.Induced pluripotent sTME cell-derived natural killer cells gene-modified to express chimeric antigen receptor-targeting solid tumors［J］.International Journal of Hematology,2021,114(5):572-579.
［25］ZENG J,TANG SY,TOH LL,et al.Generation of "off-the-shelf" natural killer cells from peripheral blood cell-derived induced pluripotent STMEcells［J］.STME Cell Reports,2017,9(6):1796-1812.
［26］KAMIYA T,SEOW SV,WONG D,et al.Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells［J］.The Journal of Clinical Investigation,2019,129(5):2094-2106.
［27］MA R,LU T,LI Z,et al.An oncolytic virus expressing IL15/IL15Rα combined with off-the-shelf EGFR-CAR NK cells targets glioblastoma［J］.Cancer Research,2021,81(13):3635-3648.
［28］MURAKAMI T,NAKAZAWA T,NATSUME A,et al.Novel human NK cell line carrying CAR targeting EGFRvIIIinduces antitumor effects in glioblastoma cells［J］.Anticancer Research,2018,38(9):5049-5056.
［29］MULLER N,MICHEN S,TIETZE S,et al.Engineering NK cells modified with an EGFRvIII-specific chimeric antigen receptor to overexpress CXCR4 improves immunotherapy of CXCL12/SDF-1α-secreting glioblastoma［J］.Journal of Immunotherapy,2015,38(5):197-210.
［30］GENBLER S,BURGER MC,ZHANG C,et al.Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival［J］.Oncoimmunology,2015,5(4):e1119354.
［31］CHEN X,HAN J,CHU J,et al.A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases［J］.Oncotarget,2016,7(19):27764-27777.
［32］SCHNALZGER TE,DE GROOT MH,ZHANG C,et al.3D model for CAR-mediated cytotoxicity using patient-derived colorectal cancer organoids［J］.The EMBO Journal,2019,38(12):e100928.
［33］ZHANG Q,ZHANG H,DING J,et al.Combination therapy with EpCAM-CAR-NK-92 cells and regorafenib against human colorectal cancer models［J］.Journal of Immunology Research,2018,2018:4263520.
［34］SHIOZAWA M,CHANG CH,HUANG YC,et al.Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells［J］.BMC Immunology,2018,19(1):27.
［35］YU M,LUO H,FAN M,et al.Development of GPC3-specific chimeric antigen receptor-engineered natural killer cells for the treatment of hepatocellular carcinoma［J］.Molecular Therapy,2018,26(2):366-378.
［36］XIA N,HAOPENG P,GONG JU,et al.Robo1-specific CAR-NK immunotherapy enhances efficacy of 125I seed brachytherapy in an orthotopic mouse model of human pancreatic carcinoma［J］.Anticancer Research,2019,39(11):5919-5925.
［37］LEE YE,JU A,CHOI HW,et al.Rationally designed redirection of natural killer cells anchoring a cytotoxic ligand for pancreatic cancer treatment［J］.Journal of Controlled Release,2020,326:310-323.
［38］PORTILLO AL,HOGG R,POZNANSKI SM,et al.Expanded human NK cells armed with CAR uncouple potent anti-tumor activity from off-tumor toxicity against solid tumors［J］.iScience,2021,24(6):102619.
［39］KLAPDOR R,WANG S,HACKER U,et al.Improved killing of ovarian cancer STME cells by combining a novel chimeric antigen receptor-based immunotherapy and chemotherapy［J］.Human Gene Therapy,2017,28(10):886-896.
［40］CAO B,LIU M,WANG L,et al.Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer［J］.Biochemical and Biophysical Research Communications,2020,524(1):96-102.
［41］UEDA T,KUMAGAI A,IRIGUCHI S,et al.Non-clinical efficacy,safety and stable clinical cell processing of induced pluripotent sTME cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells［J］.Cancer Science,2020,111(5):1478-1490.
［42］王晓杰,陆宏,耿春花.MUC1嵌合抗原受体-基因工程NK细胞治疗难治/复发恶性实体肿瘤患者的护理［J］.当代护士(中旬刊),2019,26(32):76-78. WANG XJ,LU H,GENG CH.Care of patients with refractory/relapsed solid tumors treated with MUC1 chimeric antigen receptor-genetically engineered NK cells［J］.Contemporary Nurses (Mid-Issue),2019,26(32):76-78.
［43］NG YY,TAY JCK,WANG S.CXCR1 expression to improve anti-cancer efficacy of intravenously injected CAR-NK cells in mice with peritoneal xenografts［J］.Molecular Therapy Oncolytics,2019,16:75-85.
［44］MELAIU O,LUCARINI V,CIFALDI L,et al.Influence of the tumor microenvironment on NK cell function in solid tumors［J］.Frontiers in Immunology,2020,10:3038.
［45］PARIHAR R,RIVAS C,HUYNH M,et al.NK cells expressing a chimeric activating receptor eliminate MDSCs and rescue impaired CAR-T cell activity against solid tumors［J］.Cancer Immunology Research,2019,7(3):363-375.
［46］HUANG M,DENG J,GAO L,et al.Innovative strategies to advance CAR T cell therapy for solid tumors［J］.American Journal of Cancer Research,2020,10(7):1979-1992.

Memo

Memo:
-
Last Update: 2023-01-31